GlaxoSmithKline (GSK) has reduced its research and development workforce by approximately 350 roles across the United States and the United Kingdom. In the UK, around 50 positions have been eliminated at the company’s primary R&D center in Stevenage, with additional job cuts expected.
The restructuring is part of a broader effort to streamline GSK’s operations and focus resources on key areas of innovation and development.
**Why this matters**
These job reductions reflect ongoing changes in the pharmaceutical industry as companies adjust their strategies to remain competitive. The cuts may impact ongoing research projects and the local economies where these centers operate. Understanding these shifts is important for stakeholders, including employees, investors, and policymakers.
Source: NewsData